Full-Time

Senior Scientist

Beta Islet Team

Confirmed live in the last 24 hours

Sana Biotechnology

Sana Biotechnology

201-500 employees

Develops engineered cell therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$150k - $170kAnnually

Mid, Senior

Cambridge, MA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Stem cell biology, biochemical/biomedical Engineering or related fields with 1-3 years of direct cell therapy industry experience
  • Expertise in directed stem cell differentiations using bioreactors
  • Significant experience in optimizing suspension differentiation protocols, scalability and cryopreservation
  • Hands-on experience in Flow cytometry, Immunocytochemistry, Microscopy
  • Excellent interpersonal, organizational, and independent problem-solving skills
  • Proficiency with standard flow cytometry and imaging software (e.g., FACSDiva, FlowJo, ImageJ, Halo, etc.)
Responsibilities
  • Design and execute experiments with the goal to optimize a scalable suspension platform for SC-islet differentiation
  • Characterize and evaluate the suspension differentiation process on various parameters including purity, yield, viability, morphology and metabolites
  • Establish and improve cryopreservation protocols for pluripotent stem cells, SC-islets and intermediates
  • Incorporate emerging technologies to further optimize the SC-islet differentiation process
  • Collaborate and communicate findings with other team members
  • Maintain excellent scientific documentation and contribute to SOP development
  • Assure compliance with all relevant lab safety and biosafety regulations
  • Demonstrate Sana’s core values and the attributes that support these core values (Lead from every seat, Thrive as a team, Make it happen)

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases. Their approach focuses on addressing the root causes of diseases by repairing genes within cells or replacing damaged cells. This method allows for the creation of new types of medicines that can enhance patient outcomes. Sana's main clients include healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The company invests heavily in research and development to discover and create new treatments, which they monetize through licensing agreements, partnerships, and direct sales. Unlike many competitors, Sana's focus on cellular and genetic medicine positions them uniquely in the biotechnology sector. Their goal is to lead in the development of therapies that improve patient care by targeting diseases at their genetic and cellular origins.

Company Stage

IPO

Total Funding

$798.6M

Headquarters

Seattle, Washington

Founded

2018

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-12%

2 year growth

-27%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sana's recent FDA clearance for investigational new drug applications, such as SC262 and SC291, indicates promising progress in their clinical trials.
  • The company's ability to raise significant funds through PIPE offerings and public stock offerings demonstrates strong investor confidence and financial stability.
  • Expansion into key biotech hubs like Cambridge, MA, suggests growth opportunities and access to top-tier talent.

What critics are saying

  • The resignation of key executives like Dr. Douglas Williams could disrupt R&D momentum and strategic direction.
  • High competition in the biotechnology sector, especially in gene and cell therapy, may impact market share and revenue growth.

What makes Sana Biotechnology unique

  • Sana Biotechnology focuses on engineered cells to treat and potentially cure diseases at their genetic and cellular roots, setting it apart from traditional pharmaceutical approaches.
  • Their heavy investment in R&D and partnerships with pharmaceutical companies and research institutions provide a robust pipeline for innovative therapies.
  • Sana's hypoimmune platform, which aims to create cells that can 'hide' from the patient's immune system, is a unique technological advancement in the field.

Help us improve and share your feedback! Did you find this helpful?